Study of Cyclosporine in Post-LASIK Patients

Study Identifier
192371-018
CT.gov Identifier
NCT00991458
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Eye Care - Other
    • Study Drug
  • Cyclosporine 0.010% eye drops
  • Cyclosporine 0.005% eye drops
  • Placebo (Vehicle for Cyclosporine)
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    21 - 50 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Patient is scheduled for bilateral LASIK surgery * Patient is in good general health * Eye glasses prescription of -1 to -8
    Exclusion Criteria:
    * Significant Dry Eye * Presence of eye disease * Uncontrolled systemic disease * Previous use of RESTASIS®

    Protocol Summary

    This study will evaluate the safety and efficacy of Cyclosporine 0.005% and 0.010% eye drops administered twice daily before and following LASIK surgery.

    Study Locations

    Location
    Status
    Location
    Overland Park, Kansas, United States
    Status
    Not applicable